MIAMI--(BUSINESS WIRE)--March 30, 2006--DOR BioPharma, Inc. (AMEX:DOR) ("DOR" or the "Company") announced today its financial results for 2005. Revenues for 2005 were $3,075,736 compared to $997,482 in 2004. The revenue in both years was due to the September 2004 $5.2 million grant award from the National Institute of Allergy and Infectious Diseases (NIAID) for RiVax(TM), which was increased to $6.4 million in May 2005. This increase was awarded based on a new renegotiated F&A rate with the NIH which may be used for overhead expenditures.
